Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants

被引:23
作者
Benne, CA [1 ]
Harmsen, M [1 ]
vanderGraaff, W [1 ]
Verheul, AFM [1 ]
Snippe, H [1 ]
Kraaijeveld, CA [1 ]
机构
[1] UNIV HOSP,EIJKMAN WINKLER LAB MED MICROBIOL,UTRECHT,NETHERLANDS
关键词
influenza A virus; subunit vaccine; adjuvants; virus neutralizing antibodies;
D O I
10.1016/S0264-410X(96)00287-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The influence of various adjuvants on the development of influenza virus neutralizing antibodies and distribution of anti-influenza virus IgG isotypes after immunization of mice with influenza A (H3N2) subunit vaccine was investigated. Serum titres of influenza virus neutralizing antibodies and titres of influenza specific IgG isotypes were determined by a neutralization enzyme immunoassay (N-EIA) and a cell-associated antigen enzyme immunoassay (CA-EIA), respectively. Ser um antibody titres as measured by the two tests correlated highly (r=0.82; P<0.001). N-EIA titres were enhanced by 38- and 34-fold, when L180.5/RaLPS and FCA, respectively, were administered with I mu g of vaccine. The adjuvants e-VAC, L180.5 [W/O/W], L180.5 alone and Montanide ISA 740 were only moderately or not effective in enhancing the immune response to the 1 mu g dose of vaccine. The Q-VAC and L180. 5/RaLPS adjuvants favoured IgG2a and IgG2b isotype responses to influenza compared to the other adjuvants. We suggest that N-EIA and CA-EIA may be valuable tools to monitor the effects of adjuvants on the neutralizing antibody and antibody isotype responses after influenza vaccination. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:1039 / 1044
页数:6
相关论文
共 34 条
[1]  
ADA GL, 1986, CURR TOP MICROBIOL, V128, P1
[2]   AN ADJUVANT FORMULATION THAT SELECTIVELY ELICITS THE FORMATION OF ANTIBODIES OF PROTECTIVE ISOTYPES AND OF CELL-MEDIATED-IMMUNITY [J].
ALLISON, AC ;
BYARS, NE .
JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (02) :157-168
[3]   IMMUNOLOGICAL ADJUVANTS - DESIRABLE PROPERTIES AND SIDE-EFFECTS [J].
ALLISON, AC ;
BYARS, NE .
MOLECULAR IMMUNOLOGY, 1991, 28 (03) :279-284
[4]  
Armitage P., 2002, STAT METHODS MED RES, DOI [DOI 10.1002/9780470773666, DOI 10.1007/s00431-013-2157-6]
[5]   DEVELOPMENTS IN FOOT-AND-MOUTH-DISEASE VACCINES [J].
BARTELING, SJ ;
VREESWIJK, J .
VACCINE, 1991, 9 (02) :75-88
[6]   NEUTRALIZATION ENZYME-IMMUNOASSAY FOR INFLUENZA-VIRUS [J].
BENNE, CA ;
HARMSEN, M ;
DEJONG, JC ;
KRAAIJEVELD, CA .
JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (04) :987-990
[7]   IMMUNOGLOBULIN-G - FUNCTIONAL SITES [J].
BURTON, DR .
MOLECULAR IMMUNOLOGY, 1985, 22 (03) :161-206
[8]   IMMUNITY TO INFLUENZA IN MAN [J].
COUCH, RB ;
KASEL, JA .
ANNUAL REVIEW OF MICROBIOLOGY, 1983, 37 :529-549
[9]   IGG2A RESTRICTION OF MURINE ANTIBODIES ELICITED BY VIRAL-INFECTIONS [J].
COUTELIER, JP ;
VANDERLOGT, JTM ;
HEESSEN, FWA ;
WARNIER, G ;
VANSNICK, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 165 (01) :64-69
[10]   FAILURE OF INACTIVATED INFLUENZA VACCINE TO PROTECT AN AGED POPULATION [J].
DALESSIO, DJ ;
COX, PM ;
DICK, EC .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 210 (03) :485-&